Zoetis (ZTS) Stock Rating Upgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Zoetis (NYSE:ZTS) from a neutral rating to an overweight rating in a report published on Monday, Marketbeat reports. They currently have $100.00 price objective on the stock.

Several other research firms have also weighed in on ZTS. Stifel Nicolaus lowered Zoetis from a buy rating to a hold rating and set a $95.00 target price for the company. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research lowered Zoetis from a buy rating to a hold rating in a report on Friday, October 5th. Cantor Fitzgerald restated a buy rating and issued a $98.00 target price on shares of Zoetis in a report on Monday, October 1st. Morgan Stanley boosted their target price on Zoetis from $87.00 to $92.00 and gave the stock a hold rating in a report on Friday, August 3rd. Finally, Argus boosted their target price on Zoetis from $90.00 to $103.00 and gave the stock a buy rating in a report on Tuesday, August 14th. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $92.63.

Shares of Zoetis stock opened at $91.83 on Monday. The stock has a market cap of $44.12 billion, a PE ratio of 38.66, a PEG ratio of 1.74 and a beta of 1.01. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92. Zoetis has a 52-week low of $63.03 and a 52-week high of $94.31.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same period in the previous year, the company earned $0.53 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. Equities analysts expect that Zoetis will post 3.07 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be issued a dividend of $0.126 per share. The ex-dividend date is Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.55%. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

In other news, insider Kristin C. Peck sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $86.22, for a total transaction of $431,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Roxanne Lagano sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $92.03, for a total value of $184,060.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 213,467 shares of company stock valued at $19,502,725. Corporate insiders own 0.35% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Valeo Financial Advisors LLC lifted its holdings in shares of Zoetis by 34.4% during the second quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after buying an additional 566 shares during the last quarter. Dupont Capital Management Corp increased its position in shares of Zoetis by 2.5% during the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock valued at $2,088,000 after purchasing an additional 601 shares during the period. Dorsey Wright & Associates increased its position in shares of Zoetis by 7.9% during the second quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock valued at $714,000 after purchasing an additional 617 shares during the period. Rehmann Capital Advisory Group increased its position in shares of Zoetis by 40.5% during the second quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock valued at $187,000 after purchasing an additional 631 shares during the period. Finally, Wrapmanager Inc. increased its position in shares of Zoetis by 7.9% during the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock valued at $782,000 after purchasing an additional 672 shares during the period. Institutional investors own 89.76% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply